Precision BioSciences Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Precision BioSciences Inc. on August 31, 2023. The report addresses Item 5.02 regarding the departure of certain officers and the appointment of new personnel to key financial roles.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Resignation: Shane Barton resigned as Vice President and Corporate Controller, effective September 15, 2023. He will cease serving as the principal accounting officer on that date.
- Appointment: Alex Kelly, the Company's Chief Financial Officer, was designated by the Board of Directors to serve as the principal accounting officer effective upon Mr. Barton's departure.
- Role Transition: Mei Burris, Senior Director of Finance and Corporate Controller, will assume the responsibilities previously performed by Mr. Barton.
Outlook, Risks, and Commentary
The filing contains no guidance, outlook, or discussion of risks and contingencies. Management commentary is limited to the biographical background of Ms. Burris, noting her CPA certification and prior experience at Heat Biologics (now Nighthawk Biosciences) and Cempra Pharmaceuticals.
Key Facts for Investor Verification
- Confirm the effective date of Shane Barton's departure (September 15, 2023).
- Verify Alex Kelly's dual role as CFO and principal accounting officer.
- Review Mei Burris's background and qualifications as the incoming controller.
- Check for any subsequent filings regarding the transition of accounting responsibilities.